Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function
Authors:
Open Access
- 1 April 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (4) , 2062-2066
Abstract
This study characterized the pharmacokinetic/pharmacodynamic profiles of the Food and Drug Administration (FDA)-approved telavancin renal dose adjustment schemes. A previously published two-compartment open model with first-order elimination and a combined additive and proportional residual error model derived from 749 adult subjects in 11 clinical trials was used to simulate the individual concentration-time profiles for 10,260 subjects (NONMEM). The dosing regimens simulated were 10 mg/kg of body weight once daily for individuals with creatinine clearances (CL CR s) of >50 ml/min, 7.5 mg/kg once daily for individuals with CL CR s of 30 to 50 ml/min, and 10 mg/kg every 2 days for those with CL CR s of 90% of the simulated subjects achieved an AUC τ /MIC ratio of ≥219 for MIC values as high as 2 mg/liter. For patients with CL CR s of 0–24 (AUC from 0 to 24 h) and AUC 24–48 intervals for MICs of ≤1 mg/liter. At a MIC of 2 mg/liter, the PTAs were 89.3% and 23.6% for the AUC 0–24 and AUC 24–48 intervals, respectively. The comparable PTA profiles for the three dosing regimens across their respective dosing intervals indicate that the dose adjustments employed in phase III trials for complicated skin and skin structure infections were appropriate.Keywords
This publication has 16 references indexed in Scilit:
- Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjectsJournal of Antimicrobial Chemotherapy, 2008
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive OrganismsClinical Infectious Diseases, 2008
- Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 SubjectsAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 2006
- Tissue Penetration of Telavancin after Intravenous Administration in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2006
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2004